Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 411

1.

Rosuvastatin alters the genetic composition of the human gut microbiome.

Kummen M, Solberg OG, Storm-Larsen C, Holm K, Ragnarsson A, Trøseid M, Vestad B, Skårdal R, Yndestad A, Ueland T, Svardal A, Berge RK, Seljeflot I, Gullestad L, Karlsen TH, Aaberge L, Aukrust P, Hov JR.

Sci Rep. 2020 Mar 25;10(1):5397. doi: 10.1038/s41598-020-62261-y.

PMID:
32214138
2.

Prevalence, risk factors, and type of sleep apnea in patients with paroxysmal atrial fibrillation.

Traaen GM, Øverland B, Aakerøy L, Hunt TE, Bendz C, Sande L, Aakhus S, Zaré H, Steinshamn S, Anfinsen OG, Loennechen JP, Gullestad L, Akre H.

Int J Cardiol Heart Vasc. 2019 Dec 19;26:100447. doi: 10.1016/j.ijcha.2019.100447. eCollection 2020 Feb.

3.

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.

Bergh N, Gude E, Bartfay SE, K Andreassen A, Arora S, Dahlberg P, Dellgren G, Gullestad L, Gustafsson F, Karasson K, Rådegran G, Bollano E, Andersson B.

ESC Heart Fail. 2020 Feb 14. doi: 10.1002/ehf2.12608. [Epub ahead of print]

4.

Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population.

Sverre E, Peersen K, Weedon-Fekjær H, Perk J, Gjertsen E, Husebye E, Gullestad L, Dammen T, Otterstad JE, Munkhaugen J.

BMC Cardiovasc Disord. 2020 Feb 5;20(1):61. doi: 10.1186/s12872-020-01368-6.

5.

Elevated levels of the secreted wingless agonist R-spondin 3 in preeclamptic pregnancies.

Ueland T, Estensen ME, Grindheim G, Bollerslev J, Henriksen T, Aukrust P, Aakhus S, Gullestad L, Lekva T.

J Hypertens. 2020 Jan 27. doi: 10.1097/HJH.0000000000002362. [Epub ahead of print]

PMID:
31990902
6.

Low fibre intake is associated with gut microbiota alterations in chronic heart failure.

Mayerhofer CCK, Kummen M, Holm K, Broch K, Awoyemi A, Vestad B, Storm-Larsen C, Seljeflot I, Ueland T, Bohov P, Berge RK, Svardal A, Gullestad L, Yndestad A, Aukrust P, Hov JR, Trøseid M.

ESC Heart Fail. 2020 Jan 24. doi: 10.1002/ehf2.12596. [Epub ahead of print]

7.

Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy.

Nelson LM, Andreassen AK, Arora S, Andersson B, Gude E, Eiskjaer H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F.

Transpl Int. 2020 Jan 20. doi: 10.1111/tri.13577. [Epub ahead of print]

PMID:
31958178
8.

Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.

Aimo A, Januzzi JL Jr, Vergaro G, Richards AM, Lam CSP, Latini R, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, de Boer RA, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Gamble GD, Ling LH, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Ng TP, Troughton R, Doughty RN, Passino C, Emdin M.

Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1701. [Epub ahead of print]

PMID:
31919929
9.

Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages.

Lunde NN, Gregersen I, Ueland T, Shetelig C, Holm S, Kong XY, Michelsen AE, Otterdal K, Yndestad A, Broch K, Gullestad L, Nyman TA, Bendz B, Eritsland J, Hoffmann P, Skagen K, Gonçalves I, Nilsson J, Grenegård M, Poreba M, Drag M, Seljeflot I, Sporsheim B, Espevik T, Skjelland M, Johansen HT, Solberg R, Aukrust P, Björkbacka H, Andersen GØ, Halvorsen B.

Atherosclerosis. 2020 Mar;296:74-82. doi: 10.1016/j.atherosclerosis.2019.12.008. Epub 2019 Dec 14.

10.

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.

Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimarães AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Seeger J, Tchétché D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S; GALILEO Investigators.

N Engl J Med. 2020 Jan 9;382(2):120-129. doi: 10.1056/NEJMoa1911425. Epub 2019 Nov 16.

PMID:
31733180
11.

Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI).

Anstensrud AK, Woxholt S, Sharma K, Broch K, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås JK, Hopp E, Kleveland O, Stensæth KH, Opdahl A, Kløw NE, Seljeflot I, Andersen GØ, Wiseth R, Aukrust P, Gullestad L.

Open Heart. 2019 Oct 15;6(2):e001108. doi: 10.1136/openhrt-2019-001108. eCollection 2019.

12.

Response by Nytrøen et al to Letter Regarding Article, "Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia".

Nytrøen K, Rolid K, Gullestad L.

Circulation. 2019 Oct 22;140(17):e735-e736. doi: 10.1161/CIRCULATIONAHA.119.042458. Epub 2019 Oct 21. No abstract available.

PMID:
31634012
13.

Increased Complement Factor B and Bb Levels Are Associated with Mortality in Patients with Severe Aortic Stenosis.

Shahini N, Ueland T, Auensen A, Michelsen AE, Ludviksen JK, Hussain AI, Pettersen KI, Aakhus S, Espeland T, Lunde IG, Kirschfink M, Nilsson PH, Mollnes TE, Gullestad L, Aukrust P, Yndestad A, Louwe MC.

J Immunol. 2019 Oct 1;203(7):1973-1980. doi: 10.4049/jimmunol.1801244. Epub 2019 Sep 6.

PMID:
31492744
14.

Autonomic cardiovascular control changes in recent heart transplant recipients lead to physiological limitations in response to orthostatic challenge and isometric exercise.

Nygaard S, Christensen AH, Rolid K, Nytrøen K, Gullestad L, Fiane A, Thaulow E, Døhlen G, Godang K, Saul JP, Wyller VBB.

Eur J Appl Physiol. 2019 Oct;119(10):2225-2236. doi: 10.1007/s00421-019-04207-5. Epub 2019 Aug 12.

15.

Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction.

Fosshaug LE, Colas RA, Anstensrud AK, Gregersen I, Nymo S, Sagen EL, Michelsen A, Vinge LE, Øie E, Gullestad L, Halvorsen B, Hansen TV, Aukrust P, Dalli J, Yndestad A.

EBioMedicine. 2019 Aug;46:264-273. doi: 10.1016/j.ebiom.2019.07.024. Epub 2019 Jul 22.

16.

The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection.

Trøseid M, Mayerhofer CCK, Broch K, Arora S, Svardal A, Hov JR, Andreassen AK, Gude E, Karason K, Dellgren G, Berge RK, Gullestad L, Aukrust P, Ueland T.

J Heart Lung Transplant. 2019 Oct;38(10):1097-1103. doi: 10.1016/j.healun.2019.06.003. Epub 2019 Jun 19.

PMID:
31301965
17.

The Predictive Value of Depression in the Years After Heart Transplantation for Mortality During Long-Term Follow-Up.

Bürker BS, Gullestad L, Gude E, Havik OE, Relbo Authen A, Grov I, Andreassen AK, Fiane AE, Haraldsen IR, Dew MA, Andersson S, Malt UF.

Psychosom Med. 2019 Jul/Aug;81(6):513-520. doi: 10.1097/PSY.0000000000000702.

PMID:
31033937
18.

Statin-associated muscle symptoms in coronary patients: design of a randomized study.

Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E.

Scand Cardiovasc J. 2019 Jun;53(3):162-168. doi: 10.1080/14017431.2019.1612085. Epub 2019 May 13.

PMID:
31030568
19.

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.

Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L; SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.

Transplantation. 2020 Jan;104(1):154-164. doi: 10.1097/TP.0000000000002702.

PMID:
30893292
20.

Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation.

Arora S, Ofstad AP, Ulimoen GR, Birkeland KI, Endresen K, Gullestad L, Johansen OE.

Cardiovasc Diabetol. 2019 Mar 9;18(1):26. doi: 10.1186/s12933-019-0832-2.

21.

Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study.

Solberg OG, Stavem K, Ragnarsson A, Beitnes JO, Skårdal R, Seljeflot I, Ueland T, Aukrust P, Gullestad L, Aaberge L.

Catheter Cardiovasc Interv. 2019 Nov 1;94(5):660-668. doi: 10.1002/ccd.28157. Epub 2019 Feb 21.

PMID:
30790446
22.

Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia.

Nytrøen K, Rolid K, Andreassen AK, Yardley M, Gude E, Dahle DO, Bjørkelund E, Relbo Authen A, Grov I, Philip Wigh J, Have Dall C, Gustafsson F, Karason K, Gullestad L.

Circulation. 2019 May 7;139(19):2198-2211. doi: 10.1161/CIRCULATIONAHA.118.036747. Erratum in: Circulation. 2019 Oct 22;140(17):e737.

PMID:
30773030
23.

Medical and Psychosocial Factors Associated With Low Physical Activity and Increasing Exercise Level After a Coronary Event.

Peersen K, Otterstad JE, Sverre E, Perk J, Gullestad L, Moum T, Dammen T, Munkhaugen J.

J Cardiopulm Rehabil Prev. 2020 Jan;40(1):35-40. doi: 10.1097/HCR.0000000000000399.

PMID:
30720643
24.

Treatment of sleep apnea in patients with paroxysmal atrial fibrillation: design and rationale of a randomized controlled trial.

Traaen GM, Aakerøy L, Hunt TE, Øverland B, Lyseggen E, Aukrust P, Ueland T, Helle-Valle T, Steinshamn S, Edvardsen T, Khiabani Zaré H, Aakhus S, Akre H, Anfinsen OG, Loennechen JP, Gullestad L.

Scand Cardiovasc J. 2018 Dec;52(6):372-377. doi: 10.1080/14017431.2019.1567933. Epub 2019 Feb 5.

PMID:
30638392
25.

Prevalence and prognostic implication of iron deficiency and anaemia in patients with severe aortic stenosis.

Kvaslerud AB, Hussain AI, Auensen A, Ueland T, Michelsen AE, Pettersen KI, Aukrust P, Mørkrid L, Gullestad L, Broch K.

Open Heart. 2018 Dec 16;5(2):e000901. doi: 10.1136/openhrt-2018-000901. eCollection 2018.

26.

Espeland and co-workers respond.

Espeland T, Lunde IG, Amundsen BH, Gullestad L, Aakhus S.

Tidsskr Nor Laegeforen. 2018 Nov 26;138(19). doi: 10.4045/tidsskr.18.0865. Print 2018 Nov 27. Norwegian. No abstract available.

27.

sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.

Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL Jr.

J Am Coll Cardiol. 2018 Nov 6;72(19):2309-2320. doi: 10.1016/j.jacc.2018.08.2165.

28.

Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.

Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L; SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators.

Circ Heart Fail. 2018 Sep;11(9):e004050. doi: 10.1161/CIRCHEARTFAILURE.117.004050.

PMID:
30354362
29.

Myocardial fibrosis.

Espeland T, Lunde IG, H Amundsen B, Gullestad L, Aakhus S.

Tidsskr Nor Laegeforen. 2018 Oct 12;138(16). doi: 10.4045/tidsskr.17.1027. Print 2018 Oct 16. Review. English, Norwegian.

30.

Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.

Norum HM, Michelsen AE, Lekva T, Arora S, Otterdal K, Olsen MB, Kong XY, Gude E, Andreassen AK, Solbu D, Karason K, Dellgren G, Gullestad L, Aukrust P, Ueland T.

Am J Transplant. 2019 Apr;19(4):1050-1060. doi: 10.1111/ajt.15141. Epub 2018 Nov 5.

PMID:
30312541
31.

Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction.

Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Aukrust P, Gullestad L, Halvorsen B, Yndestad A.

Open Heart. 2018 Sep 18;5(2):e000765. doi: 10.1136/openhrt-2017-000765. eCollection 2018.

32.

IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.

Orrem HL, Nilsson PH, Pischke SE, Kleveland O, Yndestad A, Ekholt K, Damås JK, Espevik T, Bendz B, Halvorsen B, Gregersen I, Wiseth R, Andersen GØ, Ueland T, Gullestad L, Aukrust P, Barratt-Due A, Mollnes TE.

Front Immunol. 2018 Sep 12;9:2035. doi: 10.3389/fimmu.2018.02035. eCollection 2018.

33.

Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial.

Andreassen AK, Broch K, Eiskjær H, Karason K, Gude E, Mølbak D, Stueflotten W, Gullestad L; SCHEDULE (SCandinavian HEart transplant everolimus De-novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators.

Transplantation. 2019 Apr;103(4):781-788. doi: 10.1097/TP.0000000000002445.

PMID:
30211826
34.

Clinical features and determinants of VO2peak in de novo heart transplant recipients.

Rolid K, Andreassen AK, Yardley M, Bjørkelund E, Karason K, Wigh JP, Dall CH, Gustafsson F, Gullestad L, Nytrøen K.

World J Transplant. 2018 Sep 10;8(5):188-197. doi: 10.5500/wjt.v8.i5.188.

35.

Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N.

ESC Heart Fail. 2018 Dec;5(6):1052-1059. doi: 10.1002/ehf2.12312. Epub 2018 Aug 25.

36.

Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial.

Mayerhofer CCK, Awoyemi AO, Moscavitch SD, Lappegård KT, Hov JR, Aukrust P, Hovland A, Lorenzo A, Halvorsen S, Seljeflot I, Gullestad L, Trøseid M, Broch K.

ESC Heart Fail. 2018 Oct;5(5):977-984. doi: 10.1002/ehf2.12332. Epub 2018 Aug 7. Review.

37.

Managing patients with prediabetes and type 2 diabetes after coronary events: individual tailoring needed - a cross-sectional study.

Munkhaugen J, Hjelmesæth J, Otterstad JE, Helseth R, Sollid ST, Gjertsen E, Gullestad L, Perk J, Moum T, Husebye E, Dammen T.

BMC Cardiovasc Disord. 2018 Aug 3;18(1):160. doi: 10.1186/s12872-018-0896-z.

38.

T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.

Abraityte A, Aukrust P, Kou L, Anand IS, Young J, Mcmurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T.

Clin Res Cardiol. 2019 Feb;108(2):133-141. doi: 10.1007/s00392-018-1331-2. Epub 2018 Jul 26.

PMID:
30051179
39.

Author's response to: letter to the editor.

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE.

Heart Fail Rev. 2018 Sep;23(5):819. doi: 10.1007/s10741-018-9728-6. No abstract available.

PMID:
30043131
40.

High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes.

Heier M, Ofstad AP, Borja MS, Brunborg C, Endresen K, Gullestad L, Birkeland KI, Johansen OE, Oda MN.

Atherosclerosis. 2019 Mar;282:183-187. doi: 10.1016/j.atherosclerosis.2018.07.005. Epub 2018 Jul 6.

41.

Response to the editor.

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE.

Heart Fail Rev. 2018 Jul 2. doi: 10.1007/s10741-018-9723-y. [Epub ahead of print] No abstract available.

PMID:
29968222
42.

Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction.

Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Holven KB, Aukrust P, Gullestad L, Yndestad A, Halvorsen B.

Int J Cardiol. 2019 Jan 1;274:348-350. doi: 10.1016/j.ijcard.2018.06.093. Epub 2018 Jun 27.

PMID:
29961573
43.

Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction.

Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K, Holte E, Ryan L, Amundsen BH, Bendz B, Aakhus S, Espevik T, Halvorsen B, Mollnes TE, Wiseth R, Gullestad L, Aukrust P, Damås JK.

Int J Cardiol. 2018 Nov 15;271:1-7. doi: 10.1016/j.ijcard.2018.04.136. Epub 2018 Jun 29.

PMID:
29961572
44.

Age-dependent morbidity and mortality outcomes after surgical aortic valve replacement.

Hussain AI, Auensen A, Brunborg C, Beitnes JO, Gullestad L, Pettersen KI.

Interact Cardiovasc Thorac Surg. 2018 Nov 1;27(5):650-656. doi: 10.1093/icvts/ivy154.

PMID:
29746650
45.

The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event.

Munkhaugen J, Otterstad JE, Dammen T, Gjertsen E, Moum T, Husebye E, Gullestad L.

Eur J Prev Cardiol. 2018 Jun;25(9):923-931. doi: 10.1177/2047487318768940. Epub 2018 Apr 11.

PMID:
29635941
46.

The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE.

Heart Fail Rev. 2018 May;23(3):303-323. doi: 10.1007/s10741-018-9685-0. Review.

47.

The follow-up after myocardial infarction - is it good enough?

Munkhaugen J, Peersen K, Sverre E, Gjertsen E, Gullestad L, Dammen T, Husebye E, Otterstad JE.

Tidsskr Nor Laegeforen. 2018 Mar 5;138(5). doi: 10.4045/tidsskr.17.1050. Print 2018 Mar 6. English, Norwegian. No abstract available.

48.

Importance of physical capacity and the effects of exercise in heart transplant recipients.

Yardley M, Gullestad L, Nytrøen K.

World J Transplant. 2018 Feb 24;8(1):1-12. doi: 10.5500/wjt.v8.i1.1. Review.

49.

Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.

Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R, Tognoni G, Wikstrand J, Latini R.

Eur J Heart Fail. 2018 May;20(5):888-895. doi: 10.1002/ejhf.1146. Epub 2018 Feb 28.

50.

Determinants and Outcome of Decision Making Among Patients with Severe Aortic Stenosis.

Hussain AI, Auensen A, Brunborg C, Aakhus S, Fiane A, Pettersen KI, Gullestad L.

J Heart Valve Dis. 2017 Jul;26(4):413-422.

PMID:
29302940

Supplemental Content

Loading ...
Support Center